🇺🇸 FDA
Patent

US 9676858

Human bispecific EGFRvIII antibody and CD3 engaging molecules

granted A61KA61K2039/505A61P

Quick answer

US patent 9676858 (Human bispecific EGFRvIII antibody and CD3 engaging molecules) held by The United States of America as Represented by the Secretary Department of Health and Human Services (NIH) expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary Department of Health and Human Services (NIH)
Grant date
Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K2039/505, A61P, A61P35/00